Stock listing
NASDAQ:MLTX MoonLake Immunotherapeutics Stock
Home listing (NASDAQ) of MoonLake Immunotherapeutics
Follow MoonLake Immunotherapeutics into a list and get an email when it puts out news.
Share price · NASDAQ:MLTX
$11.07 USD +0.28 (+2.6%)
Close on Nov 20, 2026
- Day range
- $10.73 – $11.30 USDNov 20, 2026
- Volume
- 1.72M sharesNov 20, 2026
- Market cap
- $942.1M USDAt the close on Nov 20, 2026 · price × 85.11M shares outstanding
- 52-week range
- $9.46 – $23.29 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $20.06M USDMedian day 1.38M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MLTX · Home | $11.07 USD | +0.28 (+2.6%) | 1,723,798 | $10.79 | $11.30 | $10.73 | $10.79 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MLTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $11.07 | +0.28 | +2.6% | $10.79 | $11.30 | $10.73 | 1,723,798 | |
| $10.79 | -0.46 | -4.1% | $11.18 | $11.29 | $10.78 | 1,323,543 | |
| $11.25 | -0.48 | -4.1% | $11.72 | $11.80 | $10.94 | 1,165,404 | |
| $11.73 | -0.77 | -6.2% | $12.48 | $12.78 | $11.64 | 1,382,031 | |
| $12.50 | -0.37 | -2.9% | $12.86 | $13.11 | $12.40 | 1,184,173 | |
| $12.87 | -0.64 | -4.7% | $13.47 | $13.47 | $12.87 | 1,496,881 | |
| $13.51 | +0.95 | +7.6% | $12.58 | $13.90 | $12.51 | 1,932,610 | |
| $12.56 | -0.06 | -0.5% | $12.48 | $13.04 | $12.30 | 909,175 | |
| $12.62 | +1.09 | +9.5% | $11.68 | $12.91 | $11.59 | 1,579,405 | |
| $11.53 | +0.73 | +6.8% | $11.14 | $11.55 | $11.01 | 1,033,607 | |
| $10.80 | -0.76 | -6.6% | $11.11 | $11.61 | $10.67 | 1,321,209 | |
| $11.56 | -0.14 | -1.2% | $11.86 | $11.93 | $10.95 | 1,206,429 | |
| $11.70 | +0.23 | +2.0% | $11.52 | $11.72 | $11.29 | 845,529 | |
| $11.47 | -0.31 | -2.6% | $11.80 | $12.00 | $11.17 | 946,978 | |
| $11.78 | -0.79 | -6.3% | $12.44 | $12.63 | $11.71 | 1,115,499 | |
| $12.57 | +0.26 | +2.1% | $12.36 | $12.93 | $12.31 | 4,094,074 | |
| $12.31 | +0.38 | +3.2% | $11.87 | $12.38 | $11.71 | 1,196,553 | |
| $11.93 | +0.12 | +1.0% | $11.77 | $12.10 | $11.54 | 933,730 | |
| $11.81 | -0.04 | -0.3% | $11.82 | $12.45 | $11.67 | 1,511,233 | |
| $11.85 | -0.49 | -4.0% | $12.07 | $12.28 | $11.48 | 1,935,000 | |
| $12.34 | +1.69 | +15.9% | $10.70 | $13.33 | $10.65 | 6,116,200 | |
| $10.65 | +0.33 | +3.2% | $10.34 | $10.73 | $10.34 | 1,163,600 | |
| $10.32 | +0.57 | +5.8% | $9.77 | $10.48 | $9.731 | 1,237,700 | |
| $9.75 | +0.20 | +2.1% | $9.57 | $9.863 | $9.50 | 911,600 | |
| $9.55 | -0.71 | -6.9% | $10.34 | $10.34 | $9.46 | 1,380,800 | |
| $10.26 | +0.12 | +1.2% | $10.16 | $10.51 | $10.14 | 1,067,200 | |
| $10.14 | -0.27 | -2.6% | $10.30 | $10.65 | $10.01 | 1,772,800 | |
| $10.41 | -0.27 | -2.5% | $10.70 | $10.84 | $10.36 | 2,412,500 | |
| $10.68 | -0.14 | -1.3% | $10.82 | $11.00 | $10.66 | 1,206,900 | |
| $10.82 | +0.24 | +2.3% | $10.58 | $11.09 | $10.40 | 2,011,000 | |
| $10.58 | -0.19 | -1.8% | $10.75 | $10.80 | $10.00 | 3,717,300 | |
| $10.77 | -0.18 | -1.6% | $10.81 | $11.29 | $10.71 | 1,396,000 | |
| $10.95 | -0.43 | -3.8% | $11.50 | $11.50 | $10.91 | 3,051,100 | |
| $11.38 | -0.03 | -0.3% | $11.56 | $11.72 | $11.19 | 1,867,200 | |
| $11.41 | -0.06 | -0.5% | $11.64 | $11.65 | $11.03 | 1,827,800 | |
| $11.47 | -0.23 | -2.0% | $11.73 | $11.84 | $11.29 | 1,305,100 | |
| $11.70 | +0.25 | +2.2% | $11.52 | $12.00 | $11.39 | 1,994,400 | |
| $11.45 | -0.11 | -1.0% | $11.56 | $11.70 | $11.40 | 1,506,800 | |
| $11.56 | -0.48 | -4.0% | $12.04 | $12.04 | $11.53 | 1,656,900 | |
| $12.04 | -0.08 | -0.7% | $12.15 | $12.21 | $11.80 | 2,179,500 | |
| $12.12 | -0.78 | -6.0% | $12.69 | $12.83 | $12.04 | 1,901,500 | |
| $12.90 | -0.48 | -3.6% | $13.41 | $13.69 | $12.23 | 2,003,200 | |
| $13.38 | +0.83 | +6.6% | $12.73 | $13.44 | $12.54 | 2,362,000 | |
| $12.55 | +0.16 | +1.3% | $12.50 | $12.65 | $12.24 | 1,219,800 | |
| $12.39 | +0.04 | +0.3% | $12.28 | $12.50 | $12.09 | 1,803,100 | |
| $12.35 | -0.11 | -0.9% | $12.66 | $12.80 | $12.20 | 2,298,100 | |
| $12.46 | +0.26 | +2.1% | $12.29 | $12.51 | $11.88 | 2,599,700 | |
| $12.20 | -0.48 | -3.8% | $12.70 | $12.70 | $12.02 | 1,797,600 | |
| $12.68 | +0.17 | +1.4% | $12.56 | $13.00 | $12.22 | 2,331,800 | |
| $12.51 | -0.67 | -5.1% | $13.33 | $13.55 | $12.47 | 2,384,200 | |
| $13.18 | -0.54 | -3.9% | $13.58 | $13.62 | $13.12 | 1,221,600 | |
| $13.72 | -1.22 | -8.2% | $14.90 | $15.00 | $13.66 | 1,690,100 | |
| $14.94 | -0.07 | -0.5% | $14.80 | $15.43 | $14.69 | 1,464,800 | |
| $15.01 | -0.18 | -1.2% | $15.06 | $15.24 | $14.87 | 1,428,200 | |
| $15.19 | +0.13 | +0.9% | $15.08 | $15.45 | $14.98 | 841,900 | |
| $15.06 | -0.07 | -0.5% | $15.14 | $15.47 | $14.85 | 1,187,100 | |
| $15.13 | +0.08 | +0.5% | $14.99 | $15.31 | $14.83 | 662,500 | |
| $15.05 | +0.06 | +0.4% | $14.94 | $15.11 | $14.63 | 1,017,700 | |
| $14.99 | -0.54 | -3.5% | $15.60 | $15.77 | $14.97 | 699,900 | |
| $15.53 | -0.09 | -0.6% | $15.62 | $15.78 | $15.47 | 1,099,500 | |
| $15.62 | +0.06 | +0.4% | $15.50 | $15.77 | $15.34 | 1,000,300 | |
| $15.56 | +0.19 | +1.2% | $15.54 | $15.97 | $15.53 | 819,000 | |
| $15.37 | -0.39 | -2.5% | $15.68 | $15.69 | $15.23 | 1,138,100 | |
| $15.76 | -0.11 | -0.7% | $15.99 | $16.10 | $15.58 | 1,350,900 | |
| $15.87 | -0.87 | -5.2% | $16.53 | $16.74 | $15.55 | 1,367,700 |
- Ticker
- NASDAQ:MLTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Latest deck · Jun 22, 2026
Investor Day (June 2026)
Investor day · 43 slides
Latest news
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Nov 4, 2026
Closed $11.56 (-1.2%) on Nov 4, 2026
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Aug 10, 2026
Closed $17.33 (-5.1%) on Aug 10, 2026
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
Jun 23, 2026
Closed $20.00 (-5.7%) on Jun 24, 2026
MoonLake Immunotherapeutics Announces Proposed Public Offering
Jun 22, 2026
Closed $21.22 (-4.2%) on Jun 23, 2026
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Jun 21, 2026
Closed $22.16 (+15.4%) on Jun 22, 2026
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
May 10, 2026
Closed $18.84 (+10.4%) on May 11, 2026
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Mar 28, 2026
Closed $16.93 (-2.3%) on Mar 30, 2026
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Feb 22, 2026
Closed $18.68 (-0.5%) on Feb 23, 2026
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
Feb 10, 2026
Closed $15.62 (-0.8%) on Feb 10, 2026
Issued by another party
MoonLake Immunotherapeutics on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 55 in all · newest Nov 4, 2026 · oldest 2021
- Calls
- 1 call with a replay · 1 with a transcript · latest Mar 10, 2024
- Decks
- 12 decks · latest Jun 22, 2026
Where MoonLake Immunotherapeutics is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MLTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:MLTX | BOATS | United States | USD |
| BIVA:MLTXN | BIVA | Mexico | MXN |
| BMV:MLTXN | BMV | Mexico | MXN |
Valuation
Price/book 2.5× against a median of 2.4×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $543.7M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 1.32
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutics · NASDAQ:MLTX | US$942.1M | US$543.7M | n/a | n/a | n/a | 2.5× | n/a | 0.3× | 1.32 |
| Omeros Corporation · NASDAQ:OMER | US$983.7M | US$920.3M | 10.0× | 12.4× | n/a | n/a | 132.3% | n/a | 1.64 |
| Everest Medicines Ltd. · HKEX:1952 | US$981.6M | US$1.00B | n/a | 2.8× | 183× | 1.3× | −2.2% | 0.4× | n/a |
| HBM Holdings Ltd. · HKEX:2142 | US$981.4M | US$711.6M | 10.7× | 4.5× | 8.6× | 2.4× | 57.8% | 0.2× | n/a |
| Peptron, Inc. · KRX:087010 | US$979.2M | US$942.2M | n/a | 211× | n/a | 10.2× | −342.2% | 0.2× | n/a |
| City Therapeutics, Inc. · NASDAQ:CTY | US$972.4M | US$802.8M | n/a | 59.2× | n/a | n/a | −431.4% | n/a | n/a |
| Seaport Therapeutics, Inc. · NASDAQ:SPTX | US$966.2M | US$675.8M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 0.72 |
| Savara, Inc. · NASDAQ:SVRA | US$939.9M | US$840.4M | n/a | n/a | n/a | 8.7× | n/a | 0.3× | 1.42 |
| Metis TechBio Co., Ltd. Class H · HKEX:7666 | US$918.2M | US$486.7M | n/a | 222× | n/a | 2.0× | −373.2% | 0.0× | n/a |
| InventisBio, Co., Ltd. Class A · SSE:688382 | US$899.5M | US$714.3M | n/a | 67.0× | n/a | 4.6× | −533.7% | 0.0× | n/a |
| InnoCare Pharma Ltd. Class A · SSE:688428 | US$896.7M | −US$209.5M | 9.3× | −0.6× | −2.3× | 0.8× | 27.1% | 0.1× | n/a |
| Median of the others | US$969.3M | US$758.5M | 10.0× | 35.8× | 8.6× | 2.4× | −172.2% | 0.2× | 1.42 |
Forecasts
11 strong buy · 1 buy · 2 hold · 2 strong sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 30.29 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.58 · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jorge Santos da Silva | Chairman & Chief Executive Officer, Founder |
Board
| Director | Role |
|---|---|
| Catherine Moukheibir | Chairperson |
| Jorge Santos da Silva | Chairman & Chief Executive Officer, Founder |
| Andrew J. Phillips | Member |
| Ramnik Xavier | Director |
| Spike Loy | Lead Independent Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| MoonLake Immunotherapeutics (NASDAQ:MLTX) Q4 2023 Earnings Call | Sun, Mar 10, 2024 · 12:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | −1.2% |
| Q2 2026 | Aug 10, 2026 · Before open | −5.1% |
| Q1 2026 | May 11, 2026 · Before open | +10.4% |
| Q4 2025 | Feb 26, 2026 | −3.9% |
| Q3 2025 | Nov 5, 2025 · Before open | +4.5% |
| Q2 2025 | Aug 5, 2025 · Before open | +0.2% |
| Q1 2025 | May 5, 2025 · Before open | −1.0% |
| Q4 2024 | Feb 26, 2025 · Before open | +4.0% |
| Q3 2024 | Nov 7, 2024 · Before open | −1.6% |
| Q2 2024 | Aug 7, 2024 · Before open | −2.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | −1.9% |
| Q4 2023 | Feb 29, 2024 · Before open | −15.1% |
| Q3 2023 | Nov 14, 2023 · Before open | +2.0% |
| Q2 2023 | Aug 10, 2023 · Before open | +0.6% |
| Q1 2023 | May 12, 2023 · Before open | +3.8% |
| Q4 2022 | Mar 20, 2023 · Before open | −7.9% |
| Q3 2022 | Nov 14, 2022 · Before open | +0.2% |
| Q2 2022 | Aug 12, 2022 · After close | +19.4% |
| Q1 2022 | May 16, 2022 · After close | +1.5% |
| Q4 2021 | Feb 17, 2022 · After close | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (June 2026) | Investor day | 43 slides | Jun 22, 2026 |
| Investor Day (February 2026) | Investor day | 49 slides | Feb 23, 2026 |
| Technical Presentation (2026) | Technical | 17 slides | 2026 |
| SHSA 2025 (Symposium on Hidradenitis Suppurativa Advances) | Conference | 19 slides | October 2025 |
| Investor Day (March 2024) | Investor day | 102 slides | Mar 11, 2024 |
| Technical Presentation (November 2023) | Technical | 42 slides | Nov 6, 2023 |
| Investor Day (September 2023) | Investor day | 71 slides | Sep 11, 2023 |
| Investor Day (June 2023) | Investor day | 38 slides | Jun 26, 2023 |
| Investor Day (April 2023) | Investor day | 85 slides | Apr 19, 2023 |
| Investor Day (June 2022) | Investor day | 77 slides | Jun 7, 2022 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Helix Acquisition — SPAC Merger (January 2022) | SPAC merger | 33 slides | Jan 19, 2022 |
| Helix Acquisition — SPAC Merger (October 2021) | SPAC merger | 33 slides | Oct 4, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of class A ordinary shares and pre-funded warrants Made bigger: about US$200M · US$20 a share · Leerink Partners +5 Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), LifeSci Capital (co-lead), H.C. Wainwright & Co., Clear Street Use of proceeds: Research, development, pre-commercialization and commercialization of sonelokimab, if approved, and general corporate purposes | Jun 24, 2026 |
| Public offering of class A ordinary shares Announced: about US$75M · US$10.5 a share · Leerink Partners Dealers: Leerink Partners (lead) Use of proceeds: To fund research and development of sonelokimab and for general corporate purposes | Nov 5, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Helix Acquisition Corp, a blank check company (SPAC). Priced at US$10.00 a share on Oct 19, 2020.
- Price
- US$10.00 a share
- Shares offered
- 10,000,000 Class A ordinary shares
- Offering size
- US$100 million
- Underwriters' option
- Up to 1,500,000 more shares
- Listing
- HLXA on the Nasdaq Capital Market
- Underwriter
- Jefferies
- Shares delivered
- On or about Oct 22, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 28, 2020 |
| Filed publicly | Oct 1, 2020 |
| Amended twice | Newest Oct 16, 2020 |
| Shares registered with an exchange | Oct 19, 2020 |
| Declared effective by the SEC | Oct 19, 2020 |
| Final prospectus, with the price | Oct 21, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 21, 2020 |
| CERT · Exchange's certificate of listing | Oct 20, 2020 |
| EFFECT · Notice that a registration is effective | Oct 19, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 19, 2020 |
| S-1/A · Registration statement, amended | Oct 16, 2020 |
| CORRESP · Letter to the SEC | Oct 15, 2020 |
| CORRESP · Letter to the SEC | Oct 15, 2020 |
| S-1/A · Registration statement, amended | Oct 14, 2020 |
| CORRESP · Letter to the SEC | Oct 1, 2020 |
| S-1 · Registration statement | Oct 1, 2020 |
All 12 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Sep 24, 2020 |
| DRS · Draft registration statement | Aug 28, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 21, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | ||
| Cost of revenue | 2.62M | 1.38M | 13.2K | 12.4K | 4.97K | |
| Gross profit | -2.62M | -1.38M | -13.2K | -12.4K | -4.97K | |
| Research and development | 202.9M | 112.8M | 31.8M | 42.0M | 35.5M | |
| Selling, general and administrative | 42.0M | 30.3M | 22.3M | 23.0M | 4.57M | |
| Operating income | -244.8M | -143.1M | -54.1M | -65.1M | -4.57M | -105.8K |
| Depreciation and amortization | 2.62M | 1.39M | 370.0K | 164.8K | 4.97K | 206.3K |
| EBITDA | -242.2M | -141.7M | -53.8M | -64.9M | -4.57M | 100.5K |
| Interest expense | 7.25M | 0 | 0 | 591.7K | 0 | |
| Income before tax | -229.7M | -121.0M | -44.0M | -64.5M | -4.54M | -90.8K |
| Income tax | 611.0K | 282.0K | 94.0K | 36.4K | 5.71K | -206.3K |
| Net income | -227.3M | -118.9M | -36.0M | -50.0M | -4.54M | -90.8K |
| Earnings per share, basic | -3.53 | -1.89 | -0.73 | -1.70 | -0.31 | -0.01 |
| Earnings per share, diluted | -3.53 | -1.89 | -0.73 | -1.70 | -0.31 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 334.5M | 180.4M | 451.2M | 39.5M | 8.04M | 1.34M |
| Short-term investments | 59.5M | 267.6M | 59.8M | 32.6M | 0 | |
| Receivables | 4.87M | 2.84M | 1.06M | 217.1K | 148.8K | |
| Inventory | 1.32M | |||||
| Current assets | 421.7M | 474.3M | 514.2M | 76.5M | 9.64M | 1.62M |
| Property, plant and equipment | 577.0K | 722.0K | 320.9K | 49.4K | 45.7K | |
| Total assets | 424.4M | 477.9M | 526.5M | 76.8M | 9.68M | 116.6M |
| Accounts payable | 28.4M | 8.68M | 1.46M | 47.5K | 1.23M | |
| Current liabilities | 45.5M | 22.5M | 9.97M | 7.67M | 21.1M | 125.2K |
| Long-term debt | 74.1M | |||||
| Total debt | 74.1M | 0 | 3.70M | 282.6K | 15.0M | 58.1K |
| Total liabilities | 120.0M | 24.5M | 13.0M | 8.08M | 21.3M | 4.15M |
| Shareholders' equity | 304.5M | 446.8M | 495.7M | 48.9M | -11.6M | 112.5M |
| Shares outstanding | 85.1M | 62.9M | 49.1M | 29.4M | 36.9M | 14.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -196.0M | -116.6M | -42.8M | -55.9M | -611.1K | -316.7K |
| Capital spending | -35.0K | -520.0K | -284.0K | -16.0K | -50.7K | 0 |
| Free cash flow | -196.0M | -117.1M | -43.1M | -55.9M | -35.2M | -316.7K |
| Cash from investing | 203.0M | -205.6M | -25.2M | -32.3M | -50.7K | -115.0M |
| Cash from financing | 146.0M | 51.3M | 479.7M | 119.7M | -58.1K | 116.7M |
| Dividends paid | -51.9K | |||||
| Share buybacks | -50 | 0 | 0 | -6.20K | ||
| Change in cash | 154.1M | -270.7M | 411.7M | 31.5M | -669.1K | 1.34M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 10, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Aug 10, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 25, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 24, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 22, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 22, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 9, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 1, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 21, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 2, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 25, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 23, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 5, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 5, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 22, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 3, 2025 | Material contract | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 11, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2024 | Meeting outcome | SEC |
| UPLOAD · Letter from the SEC | May 13, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 7, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| 10-K/A · Annual report, amended | May 7, 2024 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Apr 29, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 24, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 11, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 5, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 29, 2024 | Insider trade | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 29, 2024 | Results | SEC |
| 8-K · Current report | Feb 26, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 15, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 15, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 14, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 21, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 20, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 8-K · Current report | Nov 6, 2023 | Current report | SEC |
| 8-K · Current report | Oct 16, 2023 | Current report | SEC |
| 4 · Change in ownership | Oct 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 12, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 11, 2023 | Current report | SEC |
| CORRESP · Letter to the SEC | Sep 7, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 6, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 1, 2023 | Management or board change | SEC |
| S-3 · Registration statement | Aug 31, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 30, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jun 29, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Jun 29, 2023 | Offer document | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 27, 2023 | Offer document | SEC |
| 424B5 · Prospectus | Jun 26, 2023 | Offer document | SEC |
| 8-K · Current report | Jun 26, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2023 | Meeting outcome | SEC |
| 8-K · Current report | May 19, 2023 | Management or board change | SEC |
| 424B5 · Prospectus | May 11, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | May 10, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 5, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 5, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 4, 2023 | Other filings | SEC |
| S-3 · Registration statement | May 1, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | May 1, 2023 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 26, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 19, 2023 | Current report | SEC |
| 4 · Change in ownership | Apr 7, 2023 | Insider trade | SEC |
This page holds 200 of 331 filings. Open Filings
Cap table
Built by 6ix from MoonLake Immunotherapeutics’ releases · as of Nov 5, 2025
- Common shares
- 85,106,685
- Fully diluted
- 85,106,685
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 85,106,685 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 85,106,685 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bihua Chen Other companies: BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Helix Acquisition Corp. III (Chairperson and CEO, Director · Since at least Jan 22, 2026); BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Feb 8, 2024); Biomea Fusion, Inc. (Director · Since at least Apr 15, 2021); Erasca, Inc. (Director · Jul 15, 2021 – Jun 22, 2023 · Past); Monte Rosa Therapeutics, Inc. (Director · Jun 23, 2021 – Jun 23, 2021 · Past); Verve Therapeutics Inc (Director · Jun 16, 2021 – Jun 21, 2021 · Past); Rain Oncology Inc (Director · Apr 22, 2021 – Apr 27, 2021 · Past); Design Therapeutics, Inc. (Director · Mar 25, 2021 – Mar 25, 2021 · Past); Prometheus Biosciences Inc (Director · Mar 11, 2021 – Mar 11, 2021 · Past); BioAtla, Inc. (Director · Dec 15, 2020 – Dec 18, 2020 · Past); Olema Pharmaceuticals, Inc. (Director · Nov 18, 2020 – Nov 23, 2020 · Past); Atea Pharmaceuticals, Inc. (Director · Oct 29, 2020 – Nov 3, 2020 · Past); Akouos Inc (Director · Jun 25, 2020 – Jun 30, 2020 · Past); Avidity Biosciences, Inc (Director · Jun 11, 2020 – Jun 16, 2020 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Aug 12, 2019 · Past); Axonics Modulation Technologies Inc (Director · Oct 30, 2018 – Oct 31, 2018 · Past); Constellation Pharmaceuticals Inc (Director · Jul 18, 2018 – Jul 18, 2018 · Past); Kezar Life Sciences, Inc. (Director · Jun 20, 2018 – Jun 25, 2018 · Past); Kiniksa Pharmaceuticals International, plc (Director · May 23, 2018 – May 29, 2018 · Past); Apellis Pharmaceuticals, Inc. (Director · Nov 8, 2017 – Nov 13, 2017 · Past); Kineta Inc. (Director · Nov 3, 2016 – Dec 14, 2017 · Past); Clearside Biomedical Inc (Director · Jun 1, 2016 – Jun 1, 2016 · Past); Cellectar Biosciences, Inc. (Director · Aug 15, 2014 – Aug 15, 2014 · Past) | CEO and Chairman, Director · Oct 19, 2020 – Oct 22, 2020 · Past |
| John Schmid Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); AnaptysBio, Inc. (Director · Since at least Feb 2, 2018); BridgeBio Oncology Therapeutics, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Xeris Biopharma Holdings, Inc. (Director · Oct 5, 2021 – Aug 12, 2024 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jan 8, 2025 · Past); Neos Therapeutics Inc (Director · Jul 2, 2018 – Mar 19, 2021 · Past) | Director · Oct 19, 2020 – Oct 19, 2020 · Past |
| Nancy Chang Other companies: Immix Biopharma, Inc. (Independent Director · Since at least Sep 8, 2025); Galera Therapeutics, Inc. (Director · Since at least Dec 30, 2024); W&T Offshore, Inc. (Director · Since at least Apr 28, 2023); SciClone Pharmaceuticals Inc (Director · Sep 17, 2013 – Oct 13, 2017 · Past); Charles River Laboratories International, Inc. (Director · Oct 24, 2007 – May 7, 2010 · Past); Tanox Inc (Director · Dec 31, 2005 – Nov 2, 2006 · Past) | Director · Oct 19, 2020 – Oct 19, 2020 · Past |
| Mark N Lampert Other companies: Immunic, Inc. (Director · Since at least Feb 17, 2026); Kymera Therapeutics, Inc. (Director · Since at least Jan 11, 2023); Olema Pharmaceuticals, Inc. (Director · Since at least Jun 10, 2022); Rain Oncology Inc (Director · Nov 8, 2022 – Jan 25, 2024 · Past); CTi Biopharma Corp (Director · Aug 9, 2022 – Jun 26, 2023 · Past) | Director · Since at least Apr 5, 2022 |
| Andrew J. Phillips Other companies: OnKure Therapeutics, Inc. (Director · Since at least Oct 4, 2024); Enliven Therapeutics, Inc. (Director · Feb 23, 2023 – Feb 6, 2025 · Past) | Member · Since at least Apr 5, 2022 |
| Catherine Moukheibir Other companies: Ironwood Pharmaceuticals, Inc. (Director · Since at least Apr 1, 2019) | Chairperson · Since at least Apr 5, 2022 |
| da Silva Jorge Santos | Chief Executive Officer, Director · Since at least Apr 5, 2022 |
| Jay Scollins | Chief Financial Officer · Oct 19, 2020 – Oct 19, 2020 · Past |
| Jorge Santos da Silva | Chairman & Chief Executive Officer, Founder · Since at least Aug 10, 2026 |
| Kara Lassen | Director · Apr 5, 2022 – Apr 5, 2022 · Past |
All 15 people
| Person | Seat |
|---|---|
| Kristian Reich | Chief Scientific Officer · Since at least Sep 2, 2025 |
| Matthias Bodenstedt | Chief Financial Officer · Since at least Apr 5, 2022 |
| Ramnik Xavier | Director · Since at least Apr 5, 2022 |
| Simon Sturge | Director · Since at least Oct 1, 2023 |
| Spike Loy | Lead Independent Director · Since at least Apr 5, 2022 |
Log in to ask 6ix AI your own questions about MoonLake Immunotherapeutics.